Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: Final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

BJU International

Volumn 105, Issue 8, 2010, Pages 1074-1081

  Iversen, Peter ^e   McLeod, David G ^a   See, William A ^b   Morris, Thomas ^c   Armstrong, Jon ^c   Wirth, Manfred P ^d  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c ASTRAZENECA   (United Kingdom)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adjuvant; Antiandrogen; Bicalutamide; Localized; Locally advanced; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; ASTHENIA; BACKACHE; CANCER LOCALIZATION; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL CARCINOMA; GYNECOMASTIA; HEART ARREST; HEART FAILURE; HEART INFARCTION; HUMAN; IMPOTENCE; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MONOTHERAPY; OVERALL SURVIVAL; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; VASODILATATION; WATCHFUL WAITING;

ADULT; AGED; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NITRILES; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS;

EID: 77950217230     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09319.x     Document Type: Article

References (25)

1. Thompson I, Thrasher JB, Aus G et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2008 177 : 2106 2131
2. Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2008 53 : 68 80
3. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997 79 : 235 246
4. Boccon-Gibod L, Bertaccini A, Bono AV et al. Management of locally advanced prostate cancer: a European consensus. Int J Clin Pract 2003 57 : 187 194
5. Berge V, Thompson T, Blackman D. Use of additional treatment for prostate cancer after radical prostatectomy, radiation therapy, androgen deprivation, or watchful waiting. Scand J Urol Nephrol 2007 41 : 198 203
6. Fleshner N, Keane TE, Lawton CA et al. Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. Prostate Cancer Prostatic Dis 2008 11 : 46 52
7. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002 360 : 103 106
8. Bria E, Cuppone F, Giannarelli D et al. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. Cancer 2009 115 : 3446 3456
9. Bolla M, Collette L, Van Tienhoven G et al. Ten year results of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: A phase III EORTC study. Int J Radiat Oncol Biol Phys 2008 72 : S30 1
10. Souhami L, Bae K, Pilepich M, Sandler H. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol 2009 27 : 2137 2143
11. Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006 7 : 472 479
12. Di Blasio CJ, Hammett J, Malcolm JB et al. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer. Can J Urol 2008 15 : 4249 4256
13. Israeli RS, Ryan CW, Jung LL. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol 2008 179 : 414 423
14. McLeod DG, Iversen P, See WA et al. Bicalutamide 150 mg plus standard care versus standard care alone for early prostate cancer. BJU Int 2006 97 : 247 254
15. See WA, Wirth MP, McLeod DG et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002 168 : 429 435
16. Wirth MP, See WA, McLeod DG et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of5.4 years. J Urol 2004 172 : 1865 1870
17. Wirth MP, Weissbach L, Marx FJ et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004 45 : 267 270
18. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999 341 : 1781 1788
19. Raina R, Pahalajani G, Agarwal A, Zippe C. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study. Asian J Androl 2007 9 : 253 258
20. Jones CU. Short-term endocrine therapy prior to and during radiation therapy improves overall survival in patients with T1b-T2b adenocarcinoma of the prostate and PSA <=20: initial results of RTOG 94-08. Presented at the Proceedings of the American Society for Radiation Oncology 51st Annual Meeting. Int J Radiat Oncol Biol Phys 2009 75 (Suppl S1 S774. Abstract LB1
21. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009 59 : 27 41
22. Harlan SR, Cooperberg MR, Elkin EP et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol 2003 170 : 1804 1807
23. Cleary PD, Morrissey G, Oster G. Health-related quality of life in patients with advanced prostate cancer: a multinational perspective. Qual Life Res 1995 4 : 207 20
24. Barry MJ. Quality of life and prostate cancer treatment. J Urol 1999 162 : 407
25. Hoffman RM, Hunt WC, Gilliland FD, Stephenson RA, Potosky AL. Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer 2003 97 : 1653 1662